Climb Bio Files Definitive Proxy Statement

Ticker: CLYM · Form: DEF 14A · Filed: Apr 25, 2025 · CIK: 1768446

Climb Bio, INC. DEF 14A Filing Summary
FieldDetail
CompanyClimb Bio, INC. (CLYM)
Form TypeDEF 14A
Filed DateApr 25, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: proxy-statement, governance, sec-filing

TL;DR

Climb Bio filed its proxy statement for the shareholder meeting. Vote your shares!

AI Summary

Climb Bio, Inc. (formerly Eliem Therapeutics, Inc.) filed a definitive proxy statement (DEF 14A) on April 25, 2025, for its fiscal year ending December 31, 2024. The company, operating in pharmaceutical preparations, is headquartered in Wellesley Hills, MA. This filing is related to the company's annual meeting and shareholder matters.

Why It Matters

This filing provides shareholders with essential information regarding upcoming votes and company governance, allowing them to make informed decisions about their investment.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (DEF 14A) and does not contain new material financial or operational information.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of a DEF 14A filing?

A DEF 14A filing, or Definitive Proxy Statement, is used by companies to solicit proxy votes from shareholders for an upcoming shareholder meeting, providing details on matters to be voted upon.

When was this filing made?

This filing was made on April 25, 2025.

What is Climb Bio, Inc.'s former name?

Climb Bio, Inc.'s former name was Eliem Therapeutics, Inc., with a date of name change on February 19, 2019.

What is the company's primary business sector?

Climb Bio, Inc. operates in the Pharmaceutical Preparations sector, with SIC code 2834.

Where is Climb Bio, Inc. located?

Climb Bio, Inc. is located at 20 William Street, Suite 145, Wellesley Hills, MA 02481.

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 regarding Climb Bio, Inc. (CLYM).

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing